PMID- 24383972
OWN - NLM
STAT- MEDLINE
DCOM- 20140320
LR  - 20220331
IS  - 0125-877X (Print)
IS  - 0125-877X (Linking)
VI  - 31
IP  - 4
DP  - 2013 Dec
TI  - Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic 
      lupus erythematosus: a comparison using control sera obtained from healthy 
      individuals and patients with multiple medical problems.
PG  - 292-8
LID - 10.12932/AP0272.31.4.2013 [doi]
AB  - BACKGROUND: Antinuclear antibodies (ANA) and anti-double stranded DNA 
      (anti-dsDNA) are often tested as a screening tool in patients with suspected 
      systemic lupus erythematosus or connective tissue diseases. ANA can be seen in 
      healthy controls (HC) and patients with multiple medical problems (MMP). 
      OBJECTIVE: To determine the sensitivity and specificity of ANA and anti-dsDNA in 
      SLE patients, using sera from HC and MMP patients. METHODS: Serum samples from 
      HC, MMP and SLE patients, 100 in each group, were analyzed for the presence of 
      ANA and anti-dsDNA, by indirect immunofluorescent assay, using a HEp-2 cell and 
      Crithidia luciliae as substrates, respectively. RESULTS: The prevalence of ANA at 
      a titer of >/=1:80 and >/= 1:160 was 8% and 4%, respectively, in HC; and it was 12% 
      and 6% respectively, in MMP patients. The prevalence of anti-dsDNA was 0% in HC 
      and 3% in MMP patients. When using HC sera for the diagnosis of SLE, the 
      sensitivity of ANA at a titer of >/= 1:80 and >/= 1:160 was 98% and 90%, 
      respectively, with specificity of 92% and 96%, respectively. The specificity 
      decreased to 88% and 94%, respectively, when using sera from MMP patients. The 
      specificity of anti-dsDNA was 100% and 97%, when using sera from HC and MMP 
      patients, respectively. CONCLUSION: ANA and anti-dsDNA gave high sensitivity and 
      high specificity in patients with SLE, even when using MMP patient's sera as 
      controls. Physicians should take care in interpreting ANA and anti-dsDNA results 
      in MMP patients who do not have signs or symptoms of SLE or connective tissue 
      diseases.
FAU - Wichainun, Ramjai
AU  - Wichainun R
AD  - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, 
      Chiang Mai University, Chiang Mai 50200, Thailand.
FAU - Kasitanon, Nuntana
AU  - Kasitanon N
FAU - Wangkaew, Suparaporn
AU  - Wangkaew S
FAU - Hongsongkiat, Sith
AU  - Hongsongkiat S
FAU - Sukitawut, Waraporn
AU  - Sukitawut W
FAU - Louthrenoo, Worawit
AU  - Louthrenoo W
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Allergy Immunol
JT  - Asian Pacific journal of allergy and immunology
JID - 8402034
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Antibodies, Antinuclear/*blood
MH  - Autoantibodies/*blood
MH  - Autoantigens/immunology
MH  - DNA/immunology
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*blood/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
EDAT- 2014/01/05 06:00
MHDA- 2014/03/22 06:00
CRDT- 2014/01/04 06:00
PHST- 2012/07/13 00:00 [received]
PHST- 2012/09/25 00:00 [accepted]
PHST- 2014/01/04 06:00 [entrez]
PHST- 2014/01/05 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - 10.12932/AP0272.31.4.2013 [doi]
PST - ppublish
SO  - Asian Pac J Allergy Immunol. 2013 Dec;31(4):292-8. doi: 
      10.12932/AP0272.31.4.2013.